Prothena Corp Public

PRTANasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$461.519 M

$8.99 +5.64%

Close of 22 Sept 2026

Revenue

$9.68M

#3161 by revenue

Earnings

-$244.1M

Loss-making

Shares outstanding

51,336,974

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#208Puma BiotechnologyPBYI$506.9M
#209Contineum TherapeuticsCTNM$504.1M
#210Prothena Corp PublicPRTA$461.5M
#211Turn TherapeuticsTTRX$455.5M
#212Atea PharmaceuticalsAVIR$452.4M

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of Prothena Corp Public, worth $1.61M. Grants and option exercises are excluded.

William P. Scully$843.5K
100,000 shares at $8.43 on 18 Sept 2026 · filed 21 Sept 2026
William P. Scully$439.4K
50,000 shares at $8.79 on 20 Aug 2026 · filed 21 Aug 2026
William P. Scully$323.2K
37,500 shares at $8.62 on 7 Aug 2026 · filed 10 Aug 2026

What if Prothena Corp Public were worth as much as…

Open the what-if tool →

Gold $30.2T

$588,931.67

Per share 65,510× higher

Bitcoin $1.74T

$33,925.94

Per share 3,774× higher

Nvidia $5.52T

$107,442.39

Per share 11,951× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Prothena Corp Public are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.